长链非编码RNA TUG1在膀胱尿路上皮癌中的表达以及预测患者临床预后的价值

杨俊; 程帆

doi:10.13201/j.issn.1001-1420.2019.12.005

长链非编码RNA TUG1在膀胱尿路上皮癌中的表达以及预测患者临床预后的价值

杨俊^1,2,
程帆^1, ,

- 1. 武汉大学人民医院泌尿外科(武汉, 430060);
- 2. 洪湖市中医医院泌尿外科

详细信息

通讯作者: 程帆,E-mail:urology1969@aliyun.com

中图分类号: R737.14

收稿日期: 2018-09-13

Expression of long non-coding RNA TUG1 in urothelial carcinoma of the bladder and its value in predicting clinical prognosis

YANG Jun^1,2,
CHENG Fan^1, ,

- 1. Department of Urology, People's Hospital of Wuhan University, Wuhan, 430060, China;
- 2. Department of Urology, Honghu Chinese Medicine Hospital

More Information

Corresponding author: CHENG Fan, E-mail: urology1969@aliyun.com

Received Date: 13 September 2018

摘要

摘要: 目的：探讨膀胱尿路上皮癌组织中长链非编码RNA TUG1（lncRNA-TUG1）的表达量及其与膀胱尿路上皮癌患者临床预后之间的相关性。方法：qRT-PCR法检测68例膀胱尿路上皮癌组织及其癌旁正常组织中lncRNA-TUG1的表达量，分析lncRNA-TUG1在膀胱尿路上皮癌组织中表达水平与膀胱尿路上皮癌患者临床病理之间的相关性及其与患者术后临床预后之间的关系。结果：lncRNA-TUG1在膀胱尿路上皮癌组织中的表达呈异常增高趋势，其表达水平明显高于癌旁正常组织（3.57±0.66 vs.1.00±0.26，P=0.002 1）。膀胱尿路上皮癌组织中高表达水平的lncRNA-TUG1与肿瘤的组织学分级、临床分期以及淋巴结转移具有显著相关性，而与患者的性别、年龄、肿瘤直径等无关。lncRNA-TUG1高表达组膀胱尿路上皮癌患者的术后5年生存率明显低于lncRNA-TUG1低表达组膀胱尿路上皮癌患者，差异有统计学意义（P=0.012 6）。高表达水平的lncRNA-TUG1、高组织学分级、高临床分期以及发生淋巴结转移均为影响膀胱尿路上皮癌患者临床预后的独立危险因素。结论：lncRNA-TUG1在膀胱尿路上皮癌组织中的表达量明显增多，且与膀胱尿路上皮癌患者术后的临床预后密切相关，可作为预测膀胱尿路上皮癌患者预后的独立危险因素和治疗靶点。
- 膀胱尿路上皮癌 /
- 长链非编码RNA /
- TUG1 /
- 预后
Abstract: Objective: To investigate the expression of long non-coding RNA TUG1 in urothelial carcinoma of the bladder and its correlation with the clinical prognosis of patients. Method: RT-PCR was used to detect the expression of TUG1 in 68 cases of urothelial carcinoma of the bladder tissues and adjacent non-cancerous tissues, and the correlation between TUG1 expression level and clinicopathological features and the clinical prognosis of patients after operation was analysed. Result: The expression of TUG1 in urothelial carcinoma of the bladder tissues was abnormally high, and its expression level was higher than that of adjacent non-cancerous tissues(3.57±0.66 vs. 1.00±0.26, P=0.002 1). Subsequently, χ² test suggested that the high expression level of TUG1 was significantly correlated with the histological grade, clinical stage and lymph node metastasis of the tumor, but not with the sex, age or tumor diameter of the patients. Then, the results showed that the postoperative 5-year survival rate of patients in the TUG1 high expression group was significantly lower than that in the TUG1 low expression group, which the difference was statistically significant(P=0.012 6). Finally, the study found that high expression level of TUG1, high histological grade, high clinical stage and lymph node metastasis were independent risk factors that affected the clinical prognosis of patients.Conclusion: The expression of TUG1 in urothelial carcinoma of the bladder significantly increased, and it is closely related to the clinical prognosis of patients, which can be used as an independent risk factor for predicting the prognosis of patients and a therapeutic target.
- urothelial carcinoma of the bladder /
- long non-coding RNA /
- TUG1 /
- prognosis

HTML全文

参考文献(23)

[1]	韩苏军, 张思维, 陈万青, 等.中国膀胱癌发病现状及流行趋势分析[J].癌症进展, 2013, 11(1):89-95.
[2]	龚静, 陈铌, 周桥.膀胱尿路上皮癌的病理诊断进展[J].现代泌尿外科杂志, 2016, 21(9):661-666.
[3]	李旭, 艾斌.膀胱尿路上皮癌免疫治疗进展[J].药品评价, 2017, 14(2):21-26.
[4]	黄传书, 蒋国松, 黄超.膀胱癌治疗基础及临床转化研究的前沿和热点[J].临床泌尿外科杂志, 2017, 32(10):735-740.
[5]	毛健伟, 李庆文.肌层浸润性膀胱癌的治疗进展[J].中华全科医学, 2013, 11(5):778-780.
[6]	刘正升, 陈磊, 邢金春.膀胱癌新型基因和生物标记物研究进展[J].临床泌尿外科杂志, 2017, 32(2):157-160.
[7]	张佳伟, 祝清国.膀胱癌分子生物学标志物的研究进展[J].医学综述, 2017, 23(9):1742-1746.
[8]	杨峰, 易凡, 曹慧青, 等.长链非编码RNA研究进展[J].遗传, 2014, 36(5):456-468.
[9]	宋尚卿, 王林辉.长链非编码RNA与肿瘤相关性研究进展[J].实用肿瘤杂志, 2014, 29(3):287-293.
[10]	余菁雯, 周留林.长链非编码RNA与肿瘤相关信号通路研究进展[J].现代肿瘤医学, 2017, 25(23):3905-3909.
[11]	李子祺, 丁明霞, 王剑松.长链非编码RNA在膀胱肿瘤中的研究进展[J].医学综述, 2015, 21(4):632-634.
[12]	赵家荣, 晁旭.长链非编码RNA在肿瘤发生、发展中的作用研究进展[J].转化医学杂志, 2017, 6(3):129-131, 150.
[13]	肖毅, 张雁钢, 郭强.膀胱肿瘤预后相关的分子指标的研究进展[J].中国现代医生, 2017, 55(3):161-164.
[14]	徐子程, 蔡宏宙, 喻彬, 等.膀胱肿瘤相关抗原在中国人群膀胱尿路上皮癌诊断中的应用[J].临床泌尿外科杂志, 2016, 31(10):900-902.
[15]	张超, 姚欣.长链非编码RNA在膀胱尿路上皮癌中的研究进展[J].中国肿瘤临床, 2017, 44(17):890-893.
[16]	余淦, 陶启业, 欧正岳, 等.长链非编码RNA PTENP1在膀胱癌中的表达调控及功能研究[J].临床泌尿外科杂志, 2017, 32(10):746-750.
[17]	Luan W, Zhou Z, Ni X, et al.Long non-coding RNA H19 promotes glucose metabolism and cell growth in malignant melanoma via miR-106a-5p/E2F3 axis[J].J Cancer Res Clin Oncol, 2018, 144(3):531-542.
[18]	Li T, Zhu J, Wang X, et al.Long non-coding RNA lncTCF7 activates the Wnt/beta-catenin pathway to promote metastasis and invasion in colorectal cancer[J].Oncol Lett, 2017, 14(6):7384-7390.
[19]	Luo Y, Wang C, Yong P, et al.Decreased expression of the long non-coding RNA SLC7A11-AS1 predicts poor prognosis and promotes tumor growth in gastric cancer[J].Oncotarget, 2017, 8(68):112530-112549.
[20]	Li W X, Sha R L, Bao J Q, et al.Expression of long non-coding RNA linc-ITGB1 in breast cancer and its influence on prognosis and survival[J].Eur Rev Med Pharmacol Sci, 2017, 21(15):3397-3401.
[21]	Li G, Liu K, Du X.Long Non-Coding RNA TUG1 Promotes Proliferation and Inhibits Apoptosis of Osteosarcoma Cells by Sponging miR-132-3p and Upregulating SOX4 Expression[J].Yonsei Med J, 2018, 59(2):226-235.
[22]	Guo P, Zhang G, Meng J, et al.Upregulation of long non-coding RNA TUG1 promotes bladder cancer cell 5 proliferation, migration and invasion by inhibiting miR-29c[J].Oncol Res, 2018, 26(7):1083-1091.
[23]	Han Y, Liu Y, Gui Y, et al.Long intergenic non-coding RNA TUG1 is overexpressed in urothelial carcinoma of the bladder[J].J Surg Oncol, 2013, 107(5):555-559.